June 24, 2022: 

Register now for the 2022 Big Ten CRC Summit held Saturday, November 19, 2022, in Columbus, Ohio.

We invite all senior/junior faculty and fellows involved in clinical oncology research, basic scientists involved in drug discovery and translational research, cancer center leadership and administration, community leaders and patient advocates to join us in Columbus at no cost for registration. Industry leaders and medical science liaisons are invited to the summit and to give pipeline presentations for a fee. Read More

May 20, 2022: 

Joseph Maakaron, MD of the Masonic Cancer Center at the University of Minnesota, and Kalyan Vara Ganesh Nadiminti, MBBS of the University of Wisconsin Carbone Cancer Center have been appointed as co-chairs of the Bone Marrow/Stem Cell Transplant Clinical Trial Working Group. Read More

May 11, 2022:

Seven Big Ten Cancer Research Consortium (Big Ten CRC) abstracts will be highlighted during the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting held in Chicago, IL. Read More

April 20, 2022:

This month, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J, Solove Research Institute (OSUCCC) as our featured member. OSUCCC – James member Dwight Owen, MD, MSc is a medical oncologist and member of the Translational Therapeutics Program at the OSUCCC- James. Dr. Owen is a member of the Big Ten CRC’s correlative sciences clinical trial working group and a co-chair of the thoracic clinical trial working group. Dr. Owen shares why he is glad to be part of the Big Ten Cancer Research Consortium. Read More

April 13, 2022:

When I was recruited to Ohio State in 2009 as director of the Department of Radiation Oncology, one of our long-term goals was to extend our therapeutic reach by establishing central Ohio’s first proton therapy center in partnership with nearby Nationwide Children’s Hospital.

The center would enable both adult and pediatric patients to receive the very latest radiotherapy – namely proton therapy – in one facility that is closer to their homes, making it a less disruptive life experience. Proton therapy uses protons, or positively charged particles found within atoms, instead of X-rays to kill cancer cells. Because it more precisely targets tumor cells, it limits radiation exposure and potential damage to surrounding tissue and organs, reducing the chance of short- and long-term side effects. This is especially important for pediatric patients, whose bodies are still developing. Read More

March 10, 2022: 

This month, the Big Ten Cancer Research Consortium (Big Ten CRC) highlights the University of Michigan Rogel Cancer Center as our featured member. Rogel Cancer Center member Ryan Wilcox, MD, PhD, is an associate professor of hematology/oncology at Rogel and a member of the Big Ten CRC’s lymphoid malignancies clinical trial working group. He has participated in two BTCRC trials. Dr. Wilcox shares why he’s glad to be part of the Big Ten Cancer Research Consortium. Read More

March 1, 2022:

Manish Patel, DO and Naomi Fujioka, MD from the Masonic Cancer Center at the University of Minnesota were recently appointed as co-chairs of the Big Ten Cancer Research Consortium’s Head and Neck Clinical Trial Working Group. Read More

February 24, 2022:

Just over 50 years ago, President Richard Nixon signed the National Cancer Act – more commonly known as the “War on Cancer.” While harnessing the resources of the federal government was an important step forward, many have commented (including current NCI director Dr. Ned Sharpless) the effort was simultaneously ambitious and naïve. Naïve in the sense that we did not yet understand our enemy. About 25 years into the “war,” the New England Journal of Medicine published an article entitled, “Cancer Undefeated” wherein declining death rates were attributed to changing incidence rates and early detection practices (Bailar, et al. N Engl J Med 336:1569 1997 PMID: 9164814), not because of advances in therapy. Read More

February 23, 2022:

This month, the Big Ten Cancer Research Consortium highlights the Masonic Cancer Center at the University of Minnesota and physician-scientist Emil Lou, MD, PhD, FACP.

Investigator Spotlight: Emil Lou, MD, PhD, FACP (@cancerassassin1), Associate Professor in the Department of Medicine, Division of Hematology, Oncology and Transplantation, Department of Medicine and Graduate Faculty Program member in the Integrative Biology and Physiology Program (IBP) at the University of Minnesota; and Medical Director of the UMN Masonic Cancer Center’s Clinical Trials Office (CTO)-Solid Tumor Unit. Read More

February 18, 2022:

Big Ten Cancer Research Consortium investigators presented a Trial in Progress abstract at the 2022 American Society of Clinical Oncology Genitourinary Cancer Symposium. The abstract titled, A single arm, phase I/II trial of neoadjuvant androgen deprivation, darolutamide, and ipatasertib in men with localized, high-risk prostate cancer, is led by David J VanderWeele, MD, PhD of the Robert H Lurie Comprehensive Cancer Center of Northwestern University. Read More